Home > Website archive > News and media > News archives > 2016 > 06 > LSE Health publish study on antibiotic innovation

LSE Health publish study on antibiotic innovation

antibiotics 480 343

LSE Health has published a study, commissioned by the Dutch government, outlining a range of policy recommendations for improving the global research and development agendas for antibiotics.

Targeting Innovation in Antibiotic Drug Discovery reviews and analyses the existing European and international initiatives to support innovation of novel antibiotic drugs. The findings from the report provided a platform for discussion among European Ministers of Health and Ministers of Agriculture during the 2016 Ministerial Conference on AMR.

Edith Schippers, the Dutch Minister of Health says: “Resistance to available antibiotics is one of the biggest threats to public health and our healthcare systems.

“The consequences of antibiotic resistance are beyond our imagination, that is why I have put antibiotic resistance high on the agenda of the Dutch Presidency.”

Key findings include:

  • Antibiotic patents have declined by 34.8% between 2007 to 2012.
  • There are at least 52 products in the EU and US antibiotic development pipeline, but very few of them target the most deadly pathogens or have novel mechanisms of action.
  • European public investment in antibiotic research and development averaged €147 million annually from 2007 to 2013. The compares with an estimated US public investment of €234 million in 2015 and €382 million in 2016.
  • The unequal distribution of initiatives across the antibiotic value chain favours basic research and early drug discovery.
  • And the current set of incentives underserve small- and medium-sized enterprises, which comprise a significant portion of the research and development force.

To download an electronic copy of the study, visit LSE Health: Targeting Innovation in Antibiotic Drug Discovery: The Need for a One Health – One Europe – One World Framework



Targeting Innovation in Antibiotic Drug Discovery: The Need for a One Health – One Europe – One World Framework was written by:

  • Matthew J Renwick, Research Associate in Health Policy and Economics, LSE Health
  • Victoria Simpkin, Research Associate in Health Policy,  LSE Health
  • Elias Mossialos, Brian Abel-Smith Professor of Health Policy, LSE; Professor of Health Policy and Management, Institute of Global Health Innovation, Imperial College London; Co-Director, European Observatory on Health Systems and Policies

Image: Antibiotic Drugs CC BY-SA 2.0

For more information

Peter Carrol, LSE Press Office, telephone: + 44 (0)207 955 6939, email: p.carrol@lse.ac.uk

Posted 28 June 2016